Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday.

According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “

Several other equities research analysts have also recently commented on COLL. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 target price (down from $30.00) on shares of Collegium Pharmaceutical in a research report on Wednesday, April 19th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $22.00 target price (down from $24.00) on shares of Collegium Pharmaceutical in a research report on Thursday, May 11th. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. ValuEngine raised shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Piper Jaffray Companies set a $14.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, July 25th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $21.33.

Shares of Collegium Pharmaceutical (NASDAQ COLL) traded up 1.06% during trading on Monday, hitting $10.45. 296,844 shares of the stock traded hands. The firm’s market cap is $308.96 million. Collegium Pharmaceutical has a 12 month low of $7.37 and a 12 month high of $20.55. The company has a 50 day moving average price of $12.08 and a 200 day moving average price of $11.87.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. The firm had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $4.07 million. Analysts anticipate that Collegium Pharmaceutical will post ($3.00) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Upgrades Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to “Hold”” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/14/zacks-investment-research-upgrades-collegium-pharmaceutical-inc-nasdaqcoll-to-hold.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Eventide Asset Management LLC boosted its position in shares of Collegium Pharmaceutical by 3.7% in the first quarter. Eventide Asset Management LLC now owns 2,153,612 shares of the specialty pharmaceutical company’s stock worth $21,665,000 after buying an additional 75,861 shares during the period. Sectoral Asset Management Inc boosted its position in shares of Collegium Pharmaceutical by 41.4% in the second quarter. Sectoral Asset Management Inc now owns 1,808,750 shares of the specialty pharmaceutical company’s stock worth $22,627,000 after buying an additional 529,503 shares during the period. Macquarie Group Ltd. boosted its position in shares of Collegium Pharmaceutical by 37.1% in the second quarter. Macquarie Group Ltd. now owns 1,118,691 shares of the specialty pharmaceutical company’s stock worth $13,995,000 after buying an additional 302,892 shares during the period. Morgan Stanley boosted its position in shares of Collegium Pharmaceutical by 684.8% in the first quarter. Morgan Stanley now owns 885,268 shares of the specialty pharmaceutical company’s stock worth $8,906,000 after buying an additional 772,464 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Collegium Pharmaceutical by 7.8% in the first quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock worth $8,113,000 after buying an additional 58,398 shares during the period. 82.13% of the stock is owned by institutional investors.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.